NeurogesX, Inc. Files Registration Statement For $69M Initial Public Offering Of Common Stock

SAN CARLOS, Calif., Feb. 7 /PRNewswire/ -- NeurogesX, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission on Form S-1 for a proposed initial public offering of its common stock. All the offered shares will be sold by NeurogesX and the company expects to grant an option to the underwriters to purchase up to an additional 15% of the shares offered solely to cover over-allotments.

Morgan Stanley & Co. Incorporated will act as the sole book runner and lead manager for the offering. In addition, Pacific Growth Equities, LLC, Lazard Capital Markets LLC and Susquehanna Financial Group, LLLP will act as co-managers of the offering. The number of shares to be offered and the price range for the offering have not yet been determined. When available, prospectuses may be obtained from the Morgan Stanley & Co. Incorporated prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by telephone at (212) 761-6775 or by emailing prospectus@morganstanley.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Contact: Stephen Ghiglieri (650) 508-2116

Source: NeurogesX, Inc.

>>> Discuss This Story